The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
HYMPAVZI’s safety profile was generally favorable
Captured microbes are then neutralized on engineered microbicidal surfaces
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
